PFE vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PFE Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pfizer Inc. (PFE) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, PFE trades at 9.3x Forward P/E with 29.1% operating margin (-0.4% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, PFE sits in CONSOLIDATION (58th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PFE Revenue | MRNA Revenue | PFE Op. Margin | MRNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $40.8B | $140M | 27.3% | -306.0% | PFE |
| FY2019 | $40.9B | $60M | 39.2% | -906.8% | PFE |
| FY2020 | $41.6B | $800M | 22.0% | -95.0% | PFE |
| FY2021 | $73.6B | $18.5B | 29.8% | 72.0% | MRNA |
| FY2022 | $91.8B | $19.3B | 34.2% | 48.9% | MRNA |
| FY2023 | $50.9B | $6.85B | 4.2% | -61.9% | PFE |
| FY2024 | $63.6B | $3.24B | 12.6% | -121.9% | PFE |
| FY2025 | $62.6B | $1.94B | 12.4% | -158.1% | PFE |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PFE | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $157.0B | $80.7B | Larger Scale | PFE |
| Trailing P/E Ratio Valuation | 39.3x | 23.0x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 9.3x | 23.0x | Lower Multiple | PFE |
| Revenue Growth (YoY) Growth | -0.4% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | 29.1% | -80.8% | Higher Margin | PFE |
| Net Profit Margin Profitability | 6.3% | -110.5% | Higher Margin | PFE |
| Return on Equity (ROE) Capital Efficiency | 4.5% | -34.5% | Higher ROE | PFE |
| 52-Week Range Position Momentum | 48% ($24โ$31) | 67% ($22โ$281) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 22% Vol | 2.23ฮฒ ยท 78% Vol | Lower Realized Risk | PFE |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 40.3 / 100 (SELL) | Higher Composite | PFE |